Skip to main content

Nasdaq IPOs

German biotech CureVac prices US IPO at $16 high end

6 years 1 month ago
CureVac, a German Phase 1 biotech developing an mRNA vaccine for SARS-CoV-2, raised $213 million by offering 13.3 million shares at $16, the high end of the range of $14 to $16. The company raised an additional $118 million in a concurrent private placement to insider Dietmar Hop
Renaissance Capital

Chinese realty giant KE Holdings prices US IPO above the range at $20

6 years 1 month ago
KE Holdings, China's largest housing platform operating under the Lianjia and Beike brands, raised $2.1 billion by offering 106 million ADSs at $20, above the range of $17 to $19. Insiders indicated on $800 million worth of ADSs in the offering (38% of the deal). KE Holdings plan
Renaissance Capital

Chinese realty giant KE Holdings prices US IPO above the range at $20

6 years 1 month ago
KE Holdings, China's largest housing platform operating under the Lianjia and Beike brands, raised $2.1 billion by offering 106 million ADSs at $20, above the range of $17 to $19. Insiders indicated on $800 million worth of ADSs in the offering (38% of the deal). At IPO, the comp
Renaissance Capital

Sports SPAC RedBall Acquisition prices $500 million IPO at $10

6 years 1 month ago
RedBall Acquisition, a blank check company formed by RedBird Capital targeting the sports industry, raised $500 million by offering 50 million units at $10. To screen for upcoming or past SPAC IPOs, sign up for a free trial of IPO Pro. Each unit consists of one ordinary share and
Renaissance Capital

Oncology biotech Inhibrx sets terms for $102 million IPO

6 years 1 month ago
Inhibrx, a Phase 1 biotech using protein engineering to develop targeted therapies for cancer and rare diseases, announced terms for its IPO on Wednesday. The company previously filed to raise $75 million in June 2019 and withdrew the following November. The La Jolla, CA-bas
Renaissance Capital
Checked
8 minutes 44 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed